Lima, Peru Clinical Trials

A listing of Lima, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 104 clinical trials
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

mk-3475
cancer
measurable disease
solid tumor
pembrolizumab
Hospital Nacional Arzobispo Loayza ( Site 3208)
 (0.8 away) Contact site
  • 19 views
  • 12 Sep, 2021
  • +150 other locations
A Phase 2b Diabetic Kidney Disease Study

A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease

diabetic nephropathy
nephropathy
Research Site
 (3.5 away) Contact site
  • 54 views
  • 14 Aug, 2021
  • +115 other locations
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal Pancreatic or Colorectal Cancer

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

Oncosalud
 (2.6 away) Contact site
  • 143 views
  • 03 Sep, 2021
  • +192 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

mk-3475
external radiation
squamous cell carcinoma
chemotherapy regimen
adenocarcinoma
Hospital Nacional Arzobispo Loayza ( Site 0143)
 (0.8 away) Contact site
  • 32 views
  • 15 Sep, 2021
  • +152 other locations
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response …

mk-3475
measurable disease
metastatic head and neck squamous cell carcinoma
squamous cell carcinoma
primary tumor
Hospital Nacional Arzobispo Loayza ( Site 0703)
 (0.8 away) Contact site
  • 15 views
  • 15 Sep, 2021
  • +150 other locations
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Ovarian Cancer or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

Oncosalud
 (2.6 away) Contact site
  • 5 views
  • 28 Aug, 2021
  • +174 other locations
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Study MO39874 is an open-label, phase IIIb, single arm, multicenter study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.

programmed cell death 1 ligand 1
measurable disease
paclitaxel
triple-negative breast cancer
adenocarcinoma
Hospital Central Fap Juan Benavides Dorich; Oncology
 (1.9 away) Contact site
  • 147 views
  • 15 Sep, 2021
  • +163 other locations
Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Novartis Investigative Site
 (9.5 away) Contact site
  • 143 views
  • 15 Sep, 2021
  • +558 other locations
Evaluating Newly Approved Drugs for Multidrug-resistant TB

endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).

vasectomy
linezolid
fluoroquinolones
moxifloxacin
levofloxacin
Medecins Sans Frontieres Belgium
 (6053.5 away) Contact site
  • 223 views
  • 15 Sep, 2021
  • +7 other locations
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).

antimalarial agents
body mass index
lupus
azathioprine
induction therapy
KZR Research Site
 (4.7 away) Contact site
  • 261 views
  • 08 Sep, 2021
  • +52 other locations